Renalytix and Carna Health Partner on AI Kidney Disease Management

Renalytix and Carna Health have announced a partnership to improve how health systems identify and manage chronic kidney disease, according to a press release.

The collaboration integrates Renalytix’s FDA approved kidneyintelX.dkd test, which predicts the risk of kidney function decline in patients with type 2 diabetes and early stage chronic kidney disease, with Carna Health’s AI driven digital prevention and care management platform.

The combined approach is designed to help health systems move from traditional detection to risk guided, personalized care pathways. This integration aims to support earlier interventions for patients at risk of kidney failure and reduce the frequency of emergency dialysis starts.

The companies stated that the partnership could help address the high costs associated with chronic kidney disease, which currently exceeds 130 billion dollars in annual Medicare spending.